Elisabeth E. Fransen van de Putte

Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy

Roland Seiler, H.A.D.M. Ashab, Nicholas Erho et al. · European Urology · 2017 · 775 citations

Urology, Molecular Subtypes, Genitourinary Cancer +8

ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy

Floris H. Groenendijk, Jeroen de Jong, Elisabeth E. Fransen van de Putte et al. · European Urology · 2015 · 214 citations

Urology, Surgical Oncology, Erbb2 Mutations Characterize +10

Divergent Biological Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer

Roland Seiler, Ewan A. Gibb, Natalie Q. Wang et al. · Clinical Cancer Research · 2018 · 122 citations · Full text

Perioperative treatment and radical cystectomy for bladder cancer – a population based trend analysis of 10,338 patients in the Netherlands

Tom J.N. Hermans, Elisabeth E. Fransen van de Putte, Simon Horenblas et al. · European Journal of Cancer · 2015 · 53 citations

Trend Analysis, Radical Cystectomy, Urology +7

Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin

Elisabeth E. Fransen van de Putte, Laura S. Mertens, Richard P. Meijer et al. · World Journal of Urology · 2015 · 52 citations

Urology, Surgical Oncology, Genitourinary Cancer +5